The fight for dominance between Regeneron and Bayer’s big blockbuster eye drug Eylea and Roche’s rival Vabysmo is playing out in arenas beyond just prescription counts and sales numbers.

EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections required compared to Eylea and Vabysmo. Positive Phase 2 DME data and ...

Regeneron’s lead drug, Eylea (aflibercept), is an anti-vascular endothelial growth factor inhibitor approved for various ophthalmology indications. To counter the ongoing decline in Eylea sales ...

Earlier on Monday, Regeneron shared preliminary results from the fourth quarter that showed Eylea HD generated just $305 million in the U.S. It was a stunning drop-off from the $392 million the ...

Investing.com -- UBS has downgraded Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to "Neutral" from "Buy" given uncertainty around its key Eylea franchise. Brokerage slashed price target to $738 ...

Formycon's biosimilar candidate to Eylea in Europe and in Israel, the company said Monday. This partnership combines Teva’s (TEVA) commercial experience in biosimilars and its extensive ...

The revision comes amid concerns about the company's primary product, EYLEA, facing competition from Amgen (NASDAQ:AMGN)'s biosimilar version. The analysts noted that Regeneron's shares have been ...

Primarily, the lower-than-expected sales figures for Eylea’s high dose in the fourth quarter raised concerns, as revenues fell short of both his and market consensus estimates. This ...

Eylea (aflibercept) is a prescription drug that treats certain eye conditions. Eylea can cause side effects that range from mild to serious. An example includes cataracts, which may become a long ...

The European Commission’s decision on approval is expected in the second half of January 2025. Eylea ® (Aflibercept) is used to treat neovascular age-related macular degeneration (nAMD) and other ...

The company’s Eylea product line, particularly the Eylea HD, has promising developments with a pre-filled syringe application on track for a mid-2025 US launch. This positions it to compete effe ...